AUTHORS:
Mayya V. Uspenskaya Institute of Chemistry, St. Petersburg University, Center of Chemical Engineering, ITMO University, Saint Petersburg, Russia
Petr P. Snetkov Institute of Chemistry, St. Petersburg University, Center of Chemical Engineering, ITMO University, Saint Petersburg, Russia
Yuliya E. Generalova Institute of Chemistry, St. Petersburg University, Center of Chemical Engineering, ITMO University, Core Shared Research Facilities “Analytical Center”, St. Petersburg State Chemical Pharmaceutical University, Saint Petersburg, Russia
Svetlana N. Morozkina Institute of Chemistry, St. Petersburg University, Center of Chemical Engineering, ITMO University, Saint Petersburg, Russia

ABSTRACT:
Cardiac amyloidosis is one of the leading causes of restrictive cardiomyopathy. It is typically rapidly progressive diastolic dysfunction in a non-dilated ventricle. Due to the numerous molecular pathways involved in the development andprogression of the disease, the drug molecules useful for cardiac amyloidosis are represented only by two small molecules, introduced in clinical application relatively recently. Here we present the comparative analysis of drug delivery systems for tafamidis and diflunisal, which have been developed in our group. The biosafe and biodegradable polymeric matrixes such as hyaluronic acid, chitosan and PVA have been used. The concentration dependence and the influence of polymer matrix on drug release discussed. Important, that no burst character of release was detected in all developed drug delivery systems.

Keywords: Cardiac Amyloidosis, Tafamidis, Diflunisal, Drug Release, Drug Delivery Systems

Conference Venue: Male, Maldives
Conference Date: 5-7 November 2024

ISBN Number: 978-625-00-7517-3
DOI Number: https://doi.org/10.53375/imhsc.2024.36


PDF Download